PFIZER INC. DL-,05/ US7170811035 /
13/11/2024 07:50:30 | Chg. +0.110 | Volume | Bid07:50:30 | Ask07:50:30 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
24.760EUR | +0.45% | - Turnover: - |
24.760Bid Size: - | 24.900Ask Size: - | 139.72 bill.EUR | - | - |
GlobeNewswire
03/09
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
GlobeNewswire
22/08
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire
16/08
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
17/07
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire
27/06
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
05/06
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire
03/06
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
16/05
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
GlobeNewswire
09/05
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medic...
GlobeNewswire
30/04
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
22/03
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire
20/03
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
07/03
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
07/03
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...